Glycovax Pharma commercializes an outstanding CRM197

The new performant carrier protein developed under license from the National Research Council Canada (NRC)

Montreal, Quebec, Canada (date) – Glycovax Pharma Inc. has begun large-scale biomanufacturing of the CRM protein for use in human and animal vaccines. The National Research Council Canada (NRC) has developed a unique and highly efficient production system for CRM197. Glycovax has refined its production to meet regulatory requirements to levels that exceed standards for use as a vaccine component for human and animal administration. Glycovax Pharma intends to commercialize this carrier protein to meet the needs of vaccine development companies and research centers in the sector.

Carbohydrate-based vaccines are one of the most important medical innovations of the last century, having saved millions of lives from bacterial infections worldwide. To date, only a handful of proteins have been used in conjugate vaccines, CRM197 being the most widely used due to its invaluable properties. Despite its important role, large-scale production of CRM197 at reasonable cost has been a limitation for vaccine developers. Glycovax Pharma aims to make the protein more accessible to vaccine developers to better protect the health of populations.

“This agreement with the NRC marks an important milestone for our company,” said Dany Valiquette, President of Glycovax Pharma. “In the coming months, we will be able to offer CRM197 to vaccine developers, whether they be pharmaceutical, biotech or academic research companies, by guaranteeing an optimized, GMP-compliant manufacturing process. These developers will have the opportunity to evaluate our CRM197 with their own antigens, and Glycovax will support them in the regulatory aspects of their vaccine development.”